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We investigated ADAMTS13 activity as well as the ADAMTS13 gene mutation in 
children with hemolytic uremic syndrome (HUS). Eighteen patients, including 6 di-
arrhea-negative (D-HUS) and 12 diarrhea-associated HUS (D+HUS) patients, were 
evaluated. The extent of von Willebrand factor (VWF) degradation was assayed by 
multimer analysis, and all exons of the ADAMTS13 gene were PCR-amplified us-
ing Taq DNA polymerase. The median and range for plasma activity of AD-
AMTS13 in 6 D-HUS and 12 D+HUS patients were 71.8% (22.8-94.1%) and 
84.9% (37.9-119.9%), respectively, which were not statistically significantly differ-
ent from the control group (86.4%, 34.2-112.3%) (p>0.05). Five ADAMTS13 gene 
mutations, including 2 novel mutations [1584+2T>A, 3941C>T (S1314L)] and 3 
polymorphisms (Q448E, P475S, S903L), were found in 2 D-HUS and one D+HUS 
patients, which were not associated with deficiency of ADAMTS13 activity. Wheth-
er these mutations without reduced ADAMTS13 activity are innocent bystanders or 
predisposing factors in HUS remains unanswered. 
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Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura 
(TTP) are classified as thrombotic microangiopathy (TMA), which is character-
ized by occlusive microvascular thrombosis and by following thrombocytopenia, 
microangiopathic hemolytic anemia, and organ ischemia.1,2 Acute renal failure is 
prominent in HUS while neurological impairment and variable degrees of renal 
abnormalities are found in TTP.1,2 The clinical distinction between HUS and TTP 
is sometimes unclear because neurologic symptoms can be found in HUS and sig-
nificant renal insufficiency can develop in TTP.1,2
Deficiency in the von Willebrand factor (VWF)-cleaving protease, also known 
as ADAMTS13 (a disintegrin and metalloprotease, with thrombospondin 1-like do-
mains motif 13), is causatively related in 70-80% of TTP,3,4 either by compound 
heterozygous or homozygous mutations in the ADAMTS13 gene in congenital 
TTP5,6 or circulating inhibitory antibodies in the acquired form.4 
However, the focus of research in HUS has been on the mechanisms of injury to ADAMTS13 Gene Mutations in HUS 
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the remaining protease activity in the mixture of patient’s 
plasma and normal pooled plasma at different dilution. Detec-
tion of inhibitory activity was carried out by using a screening 
test, by 1 : 1 mixing pools of normal plasma and patient plas-
ma with reduced ADAMTS13 activity (less than 44%) and by 
incubating for 30 minutes at 37°C. Thereafter, the mixture 
was diluted to 1 : 10 in Tris/urea, pH 8.0, and processed fur-
ther to test ADAMTS13 activity remaining.11 
Human genomic DNA was isolated from whole blood. 
All exons of the ADAMTS13 gene, including the intron-ex-
on boundaries, were PCR-amplified with the primers used 
by Kokame, et al.6 and Taq DNA polymerase. Products 
were sequenced in both directions by using a 3700 DNA 
Analyzer (Applied Biosystems, Foster City, CA, USA).
Statistics were performed using SAS software (version 
8.2) and Chi-square test. p value less than 0.05 was consid-
ered statistically significant. 
In 18 patients tested, 6 were D-HUS, and 12 D+HUS 
(Table 1). The median and range for plasma activity of AD-
AMTS13 in 6 D-HUS and 12 D+HUS patients were 71.8% 
(22.8-94.1%) and 84.9% (37.9-119.9%), respectively, which 
were not statistically significantly different from the control 
group (86.4%, 34.2-112.3%) (p>0.05). No inhibitory activi-
ty was detected in patients with ADAMTS13 activity less 
than 44%. 
Five ADAMTS13 gene mutations consisting of 2 novel 
mutations [1584+2T>A, 3941C>T (S1314L)] and 3 poly-
morphisms [Q448E, P475S, 2710C>T (S903L)] were found 
in 3 HUS (2 D-HUS and one D+HUS) patients (Fig. 1). All 
parents of these 3 HUS patients with ADAMTS13 gene mu-
tations are clinically unaffected. Two novel mutations, 1584 
+2T>A, and S1314L, were excluded as common polymor-
phisms by screening 100 Koreans. 
More than 60 mutations of the ADAMTS13 gene have 
been found in patients with congenital TTP (The Human 
Gene Mutation Database at the Institute of Medical Genet-
ics in Cadiff, http://www.hgmd.ac.uk/ac/index.php). How-
ever, analysis of ADAMTS13 gene mutations has generally 
been restricted to patients already carrying a clear diagnosis 
of congenital TTP, potentially presenting an ascertainment 
bias against the identification of mild mutations.12
While severe deficiency of ADAMTS13 (<10%) estab-
lishes a diagnosis of TTP unequivocally,13 not all patients 
diagnosed with TTP have severe protease deficiency. In ad-
dition, ADAMTS13 deficiency alone may not be sufficient 
to initiate an episode of clinical TTP.14 Patients in clinical 
remission can still demonstrate ultralarge VWF multimers 
the renal endothelium rather than the regulation of VWF.2 
In diarrhea-associated HUS (D+HUS), the bacterial agent 
Shigatoxin from Escherichia coli and Shigella dysenteriae 
induces the thrombotic state via direct toxic effects, result-
ing more in renal injury and clinical HUS.7 In diarrhea-neg-
ative (D-HUS) or atypical HUS, more than 50% of patients 
have genetic abnormalities in complement regulatory 
genes, including complement factor H (CFH), factor I 
(CFI), membrane cofactor protein (MCP), and factor B 
(CFB) and C3.8,9 Acquired cases of D-HUS associated with 
CFH dysfunction due to anti-CFH autoantibodies have also 
been identified.8   
Considering the overlapping clinical manifestation of 
HUS and TTP, we hypothesized that ADAMTS13 would be 
an important factor in HUS, and therefore, investigated 
ADAMTS13 activity as well as ADAMTS13 gene mutation 
in children with HUS. 
The samples of 18 patients with HUS were sent to CHA 
Bundang Medical Center to test for ADAMTS13 activity 
and ADAMTS13 gene mutation from April 2004 to August 
2005. The diagnosis was based on the presence or absence 
of diarrhea, renal dysfunction, microangiopathic hemolytic 
anemia and thrombocytopenia. Eighteen normal controls 
were recruited from those who visited the Department of 
Pediatrics of CHA Bundang Medical Center in the same 
period. In cases of decreased ADAMTS13 activity (less than 
44%), the presence of autoantibody in the patient’s serum 
and the ADAMTS13 activity of the parents were tested. The 
plasma samples were collected from patients and controls 
with the informed consent, according to the guidelines of 
the Declaration of Helsinki. The study protocol was ap-
proved by the institutional review board of the CHA Bun-
dang Medical Center.
The assay of ADAMTS13 activity was performed as de-
scribed previously by Furlan, et al.3 Briefly, diluted citrated 
plasma was activated by barium chloride. This activated 
plasma was added to protease-free VWF (Green Cross, Yon-
gin, Korea). The reaction was stopped by addition of EDTA. 
The extent of VWF degradation was assayed by multimer 
analysis using SDS-electrophoresis in 1.4% agarose gels. 
Following electrophoresis, the proteins were eletrotransferred 
to nitrocellulose, and VWF was visualized with horseradish 
peroxidase-conjugated goat anti-rabbit IgG against human 
VWF (A0082, Dako, Glostrup, Denmark). The activity was 
calibrated as previously described10 with 1 : 20 to 1 : 960 
dilution of normal human plasma pool. 
Inhibition of the ADAMTS13 was assayed by measuring Hyoung Soo Choi, et al.
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leukemia, pregnancy, the postoperative state, the neonatal 
period, and with advancing age16 other than congenital TTP. 
As for HUS, ADAMTS13 activity is normal or only slightly 
decreased in typical colitis-associated D+HUS, and severe-
ly deficient in a few D-HUS.17 
In this study, ADAMTS13 activities were not decreased in 
18 HUS patients, which is consistent with previous re-
ports.18 Although the ADAMTS13 activities were normal, 
we found mutations and polymorphisms of ADAMTS13 
gene in 2 D-HUS and one D+HUS patients. We cannot ex-
plain the genotype-phenotype dissociation in our 3 HUS 
patients with ADAMTS13 gene mutations. Heterozygous 
mutation, distal location, or interaction with polymorphisms 
might be possible explanations. 
One D-HUS (patient 3) patient had heterozygous P475S 
in the plasma and absence of ADAMTS13 activity in vitro.3 
This heterogeneity suggests the presence of genetic modi-
fying factors or environmental triggers other than AD-
AMTS13 in TTP.1 
Complement factor H mutation, known as a causative 
factor in D-HUS, and Shigatoxin, inducing the thrombotic 
state in D+HUS, were reported to be risk factors in TTP.9,15 
In addition to the overlapping clinical features between 
TTP and HUS, these findings suggest possible role of AD-
AMTS13 in HUS. 
Decreased ADAMTS13 activity, usually mild to moderate 
(10 to 40% of normal plasma), has been reported in a wide 
variety of conditions, including liver cirrhosis, chronic ure-
mia, idiopathic thrombocytopenic purpura, disseminated 
intravascular coagulation, systemic lupus erythematosus, 
Table 1. Patients Characteristics  
ID Sex/Age
ADAMTS13 
(%)
CNS Sx FHx Shigatoxin C3  Recur Outcome
ADAMTS13 
Mutations
D-HUS   1 F/2 yrs 29.6 - - ND ND - Normal
  2 F/10 yrs 22.8 - - - 47 - MicroHU
    3* F/10 months 53.9 - - - 112 + Died P475S
    4* F/5 yrs 85.5 + - ND 78 + KidT/NED
1584+2T>A, 
S903L
†
  5 F/3 yrs 94.1 - - - 116 - Normal
  6 F/1 months 71.8 - + ND ND - Normal
D+HUS     7* F/17 months 96.9 - - E.coli O157 : H7 118 - Normal Q448E, S1314L
  8 F/13 yrs 119.9 - - ND ND - HTN
  9 M/10 yrs 55.7 - - - 127.7 - Normal
10 F/14 months 76.9 - - - 64 - Normal
11 F/4 yrs 76.9 - - Klebsiella 112 - Normal
12 M/4 yrs 84.9 - - ND ND - Normal
13 M/2 yrs 44.5 - - - 10.7 - Normal
14 M/3 yrs 95.1 + - - ND - Normal
15 F/3 yrs 37.9 - - - 85 - Normal
16 F/20 months 95.1 - - - ND - MicroP/HU
17 M/9 yrs 94.0 - - - ND - Normal
18 F/3 yrs 63.2 - - - 80.1 - Normal
C3 normal range 77-195 mg/dL.
FHx, family history; ND, not done; MicroHU, microscopic hematuria; KidT, kidney transplantation; HTN, hypertension; MicroP/HU, microscopic proteinuria 
and microscopic hematuria.
*Patients with ADAMTS13 gene mutations and/or polymorphisms. 
†Homozygote.
Fig. 1. ADAMTS13 gene structure and mutation sites in 3 HUS patients. *Three polymorphisms are indicated by italics. HUS, hemolytic uremic syndrome; S, sig-
nal peptide; P, propeptide; MP, metalloprotease domain; D, disintegrin-like domain; T, TSP1 motif; Cys, cysteine-rich domain; Sp, spacer domain; C, CUB domain.   
1584+2T>A S1314L
*Q448E   *P475S *S903L
S P MP D T Cy Sp T T T T T T T C CADAMTS13 Gene Mutations in HUS 
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HUS in Korean population. Whether these mutations with-
out reduced ADAMTS13 activity are innocent bystanders or 
predisposing factors in HUS remains unanswered. In TTP, 
relapse is common among patients with ADAMTS13 defi-
ciency, but rarely occurs in patients without ADAMTS13 de-
ficiency.25 In 6 D-HUS patients in this study, only the pa-
tient 3 and 4 underwent recurrent attack of HUS, suggest-
ing the possibility that ADAMTS13 gene mutations may act 
as a disease modifying or predisposing factor through an 
unexplained mechanism. 
In the future, expression tests are needed to identify the 
consequences of each ADAMTS13 gene mutations and poly-
morphisms found in our HUS patients. Abnormalities in 
complement system and other genetic or environmental 
factors, involving TMA, should be investigated. In addition, 
VWF assay and mutation analysis would be a next assign-
ment in our patients. Long-term follow-up of these HUS pa-
tients with ADAMTS13 gene mutations might also provide 
an invaluable clue.
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